Catalyst Repository | Avenue Therapeutics Inc. Common Stock

Avenue Therapeutics Inc. Common Stock

(NASDAQ:ATXI)

Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.

ATXI Overview

None
Sector
Health Care
Industry
Major Pharmaceuticals

Previous Close
$0.2703
Previous Close Volume
72050